July 19, 2012 (Vancouver, British Columbia) — EVP-6124, an experimental medication from EnVivo Pharmaceuticals, may improve symptoms in patients with Alzheimer's disease (AD), according to a new phase 2b clinical trial presented here at the Alzheimer's Association International Conference (AAIC) 2012.
Results from the study, which included more than 400 patients with mild to moderate AD, showed that the participants who received 2 mg/day of EVP-6124 for 6 months had significantly better improvement in test scores for cognition, memory, language, and other functions. The drug was also considered "well tolerated./.../
"
"
No comments:
Post a Comment